In March, the WHO initiated the "SOLIDARITY Trial" in 10 countries, enrolling thousands of people infected with COVID‑19 to assess treatment

According to one source , diverse categories of preclinical or early-stage clinical research for developing COVID‑19 therapeutic candidates included:

• antibodies (61 candidates)

• antivirals (22 candidates)

• cell-based compounds (15 candidates)

• RNA-based compounds (6 candidates)

• scanning compounds to be repurposed (18 candidates)

• various other therapy categories, such as anti-inflammatory, antimalarial, interferon, protein-based, antibiotics, and receptor-modulating compounds, among numerous others (86 candidates) for a total of 293 compounds under development in May